Clinical Trials Browser

Withdrawn × Mesothelioma, Malignant × 90 days × Clear all

NCT06654050 2026-03-17

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma